PHVS - Viridian Pharvaris said to be among prime M&A targets for Biogen
2024-07-16 11:10:14 ET
More on Biogen, Pharvaris, etc.
- Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024
- Biogen Stock: Cheapish, But With Few Growth Prospects
- Biogen Inc. (BIIB) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A
- Biogen, Eisai launch Alzheimer's drug Leqembi in China